Inhibitor challenges in the paediatric setting [1]

Haemophilia

Volumn 12, Issue 1, 2006, Pages 106-107

  Sieger, Lance ^a   Aledort, L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB;

ADJUVANT THERAPY; ANTIBODY TITER; CREUTZFELDT JAKOB DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FATALITY; HEALTH CARE COST; HEMOPHILIA; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; LETTER; MUCOSAL BLEEDING; PRIORITY JOURNAL; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ADULT; CHILD; FACTOR VII; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 33646015700     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01165.x     Document Type: Letter

References (9)

1. Ehrilich HJ, Henzel MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA ®): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
2. Manno CS. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. Haemophilia 1999; 5 (suppl 3): 33-41.
3. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (suppl 3): 25-32.
4. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
5. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P and the French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
6. Luu H, Ewenstein B. FEIBA ® safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (suppl 2): 10-6.
7. Négrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000; 26: 407-12.
8. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
9. Brackmann HH, Gormsen J. Massive factor VIII infusion in haemophiliacs with factor VIII inhibitor, high responder. Lancet 1977; 2: 933.